Check for updates

OPEN ACCESS

EDITED BY Maxine Deborah Gossell-Williams, University of the West Indies, Jamaica

REVIEWED BY

Liu Yang, Heilongjiang University of Chinese Medicine, China Wei Peng, Chengdu University of Traditional Chinese Medicine, China

*CORRESPONDENCE Sheng-Fang Xie, ⊠ xieshengfang@163.com Xue-Zhou Wang, ⊠ wxz007voa@126.com

RECEIVED 13 September 2023 ACCEPTED 22 January 2024 PUBLISHED 01 February 2024

CITATION

Zhu K-X, Wu M, Bian Z-L, Han S-L, Fang L-M, Ge F-F, Wang X-Z and Xie S-F (2024), Growing attention on the toxicity of Chinese herbal medicine: a bibliometric analysis from 2013 to 2022. *Front. Pharmacol.* 15:1293468. doi: 10.3389/fphar.2024.1293468

COPYRIGHT

© 2024 Zhu, Wu, Bian, Han, Fang, Ge, Wang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Growing attention on the toxicity of Chinese herbal medicine: a bibliometric analysis from 2013 to 2022

Ke-Xin Zhu^{1,2}, Min Wu^{1,2}, Zhi-Lin Bian^{1,2}, Shi-Liang Han^{1,2}, Li-Ming Fang^{1,2}, Feng-Feng Ge^{1,2}, Xue-Zhou Wang³* and Sheng-Fang Xie^{1,2}*

¹Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, ²Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China, ³International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China

Introduction: Despite the clinical value of Chinese herbal medicine (CHM), restricted comprehension of its toxicity limits the secure and efficacious application. Previous studies primarily focused on exploring specific toxicities within CHM, without providing an overview of CHM's toxicity. The absence of a quantitative assessment of focal points renders the future research trajectory ambiguous. Therefore, this study aimed to reveal research trends and areas of concern for the past decade.

Methods: A cross-sectional study was conducted on publications related to CHM and toxicity over the past decade from Web of Science Core Collection database. The characteristics of the publication included publication year, journal, institution, funding, keywords, and citation counts were recorded. Co-occurrence analysis and trend topic analysis based on bibliometric analysis were conducted on keywords and citations.

Results: A total of 3,225 publications were analyzed. Number of annal publications increased over the years, with the highest number observed in 2022 (n = 475). The *Journal of Ethnopharmacology* published the most publications (n = 425). The most frequently used toxicity classifications in keywords were hepatotoxicity (n = 119) or drug-induced liver injury (n = 48), and nephrotoxicity (n = 40). Co-occurrence analysis revealed relatively loose connections between CHM and toxicity, and their derivatives. Keywords emerging from trend topic analysis for the past 3 years (2019–2022) included ferroptosis, NLRP3 inflammasome, machine learning, network pharmacology, traditional uses, and pharmacology.

Conclusion: Concerns about the toxicity of CHM have increased in the past decade. However, there remains insufficient studies that directly explore the intersection of CHM and toxicity. Hepatotoxicity and nephrotoxicity, as the most concerned toxicity classifications associated with CHM, warrant more in-depth investigations. Apoptosis was the most concerned toxicological mechanism. As a recent increase in attention, exploring the mechanisms of ferroptosis in

nephrotoxicity and NLRP3 inflammasome in hepatotoxicity could provide valuable insights. Machine learning and network pharmacology are potential methods for future studies.

KEYWORDS

Chinese herbal medicine, toxicity, safety, bibliometric analysis, crosssectional, pharmacology

1 Introduction

Herbal medicine is derived from traditional medical systems and serves as an extensively employed complementary therapy in clinical practice (Barnes et al., 2016). Particularly, Chinese herbal medicine (CHM) stands as a representative within this domain, boasting a long historical lineage and even contributed China's first Nobel Prize in natural sciences (Tu, 2016). Evidence supports the protentional efficacy of CHM in treating cardiovascular (Hao et al., 2017), nephritic (Zhong et al., 2015), immunologic (Jakobsson et al., 2022) and cancer-related disorders (Yao et al., 2021). As one of the most prevalent herbal medicines, CHM is exported to over 175 countries and regions (Teng et al., 2016). Despite these promising prospects, similar to other herbal remedies, CHM encounters the hurdle of toxicity. The toxicity of CHM typically presents as hepatotoxicity and nephrotoxicity (Ekor, 2014), which are the leading causes of drug development failure or market withdrawal (Hoppmann et al., 2020; Kulkarni, 2021). Given the World Health Organization's prioritization of drug safety (Donaldson et al., 2017), emphasizing the toxicity of CHM becomes imperative.

The underestimation of the toxicity of CHM is a longstanding issue. The prescription of CHM under the guidance of traditional toxicity theory is frequently considered to be completely safe. Following the first discovery of severe toxic aristolochic acids in some Chinese herbs (Vanhaelen et al., 1994), many toxic components were determined (Lv et al., 2012). However, before the prohibition of these CHMs and synthetic drugs by countries (Hashimoto et al., 1999; Lee et al., 2002; Gabardi et al., 2007; Zhou et al., 2013), the associated herbs had been used for thousands of years. Astonishingly, the modern toxicity of some CHMs contradicts the traditional theory. For instance, Aristolochia manshuriensis Kom was traditionally believed to possess diuretic properties for treating kidney disease but was proven to be nephrotoxic and carcinogenic (Wang L. et al., 2018). Recent studies revealed that the toxicity of certain CHMs were quite complex, particularly in terms of hepatotoxicity. The toxicity of these herbs exhibits a dose-independent pattern and displays significant interindividual variability across different populations (Ma et al., 2023). In addition, the lack of quality control measures during production and sales exacerbates the risks associated with toxicity (Raynor et al., 2011; Liu et al., 2015). Such concerns prompted regulatory bodies including the Food and Drug Administration (FDA) to only approve limited CHMs (Qu et al., 2022; You et al., 2022).

Fortunately, the toxicity of CHM garnered increased attention in recent years, with various safety regulatory standards, clinical practice guidelines and manifestos highlighting the urgency of this issue (Yang et al., 2022). However, existing studies mainly focused on specific toxicities, resulting in a lack of overview to the overall safety of CHM. Additionally, there are still gaps in understanding the actual incidence rate and specific mechanisms (Teschke et al., 2014; Yang et al., 2018; Wang et al., 2022). Therefore, to provide a comprehensive understanding of the toxicity of CHM and identify potential avenues for future research, this crosssectional study aimed to reveal research trends and areas of concern for the past decade through bibliometric analysis.

2 Materials and methods

2.1 Data collection

This study included publications concerning the toxicity of CHM, and were published between 2013 and 2022. The search was conducted by the Web of Science Core Collection (WOS) database using the following strategy:

#1 TS= "toxicity" OR "toxicology" OR "nephrotoxicity" OR "hepatotoxicity" OR "drug-induced injury" OR "cardiotoxicity" OR "neurotoxicity" OR "ototoxicity" OR "hematotoxicity" OR "immunotoxicity".

#2 TS= "traditional Chinese medicine" OR "Chinese herbal" OR "Chinese herb".

- #3 FPY = 2013-2022.
- #1 AND #2 AND #3.

An additional search was conducted within the CNKI database to examine the distinctions in publication characteristics across databases. The search strategy used for the CNKI database is provided in the Supplementary Material.

2.2 Analysis

After obtaining the data of all publications, basic characteristics including title, publication year, author, author's keyword, institution, funding agency and citation were counted. VOSviewer (version 1.6.19), Bibliometrix package of R (version 4.3.0) and Citespace (version 5.7. R5) software were used for visualized analysis (van Eck and Waltman, 2010). Bibliographic coupling analysis with timeline was performed in influential journals. Influential journals were defined as the top 25 journals (\geq 5 publications on this field per journal) with the most cite frequency by the included publications. Evaluation of hotspot and trend was conducted by co-occurrence analysis and trend topic analysis based on author's keywords. Co-occurrence analysis was conducted on the 40 keywords of the most records,



TABLE 1 Top 5 productive journals, institutions and funding agencies.

Category		Counts (%)
Journal	Journal of Ethnopharmacology $(IF = 5.4, Q1)^a$	425 (13.18)
	Frontiers in Pharmacology (IF = 5.6, Q1)	226 (7.01)
	Evidence-Based Complementary and Alternative Medicine ^b	138 (4.28)
	Molecules (IF = 4.6 , Q2)	77 (2.39)
	Phytomedicine (IF = 7.9, Q1)	76 (2.36)
Institution	Beijing University of Chinese Medicine	187 (5.80)
	Chengdu University of Traditional Chinese Medicine	152 (4.71)
	Shanghai University of Traditional Chinese Medicine	146 (4.52)
	Nanjing University of Chinese Medicine	132 (4.09)
	Chinese Academy of Medical Sciences and Peking Union Medical College	118 (3.66)
Funding agency	National Natural Science Foundation of China	1,489 (46.17)
	China Postdoctoral Science Foundation	87 (2.70)
	National Basic Research Program of China	78 (2.42)
	Fundamental Research Funds for the Central Universities	74 (2.29)
	National Natural Science Foundation of Guangdong Province	65 (2.02)

^aImpact factor (IF) and quartile ranking were based on the Journal Citation Reports (JCR) data updates 18 Oct 2023.

^bThe journal no longer includes in Web of Science (WOS) journal list since 20 March 2023.

with varied colors showing the trends over time. Additional cooccurrence analysis was conducted on countries with more than 10 publications for exploring the cooperation between individual countries. Trend topic analysis was conducted on the 3 independent emerging keywords each year, with the duration of the hot topic. In trend topic analysis, keywords lasted for more than 5 years were defined as long-term concerned keywords, while the ones with the duration less than 2 years were defined as short-term concerned keywords. Co-occurrence analysis and trend topic analysis are complementary. The former selects the term of analysis by

TABLE 2 Top 5 productive authors.

Author	Counts ^a	H-index ^b
Хіао-Не, Хіао	30	87
Jia-Bo, Wang ^c	25	36
Jin-Ao, Duan	24	51
Yu-Ping, Tang	22	51
Tomas, Efferth	17	79

^aDue to the duplication of names, publications were counted by individual authors, rather than authors' name. After formatting all names manually, authors' information was verified in WOS to prevent mismatching.

^bThe h-index is an indicator based on a list of publications ranked in descending order by the Times Cited and reflects the productivity of authors based on their publication and citation records. H-index of the authors were recorded on 25 November 2023.

°Two author profiles appeared in WOS, that were verified to belong to the same individual author. Publications were combined counted and h-index was selected from the profile with more publications.



keyword frequency, which can show the connection between keywords, but may mask the recent emerging keywords. Trend topic analysis does not have the ability to show connections, but can better detect the potential hotspots. Citation burst analysis was conducted to discern emergent citations.

3 Results

The initial search yielded 3,242 records, and 17 of them were excluded for reasons including languages other than English (n = 12), retracted publication (n = 3) and correction (n = 2). A total of

Title	Corresponding author ^a	Journal	Publication year	Cited frequency ^b
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety	Ekor, M	Frontiers in Pharmacology	2014	1,416
Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment	Ning, K	Frontiers in Pharmacology	2019	530
Puerarin: A Review of Pharmacological Effects	Peng, C	Phytotherapy Research	2014	427
Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics	Ni, J	Phytotherapy Research	2016	364
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy	Efferth, T	Seminars in Cancer Biology	2017	317
Apigenin in cancer therapy: anti-cancer effects and mechanisms of action	Shao, HJ	Cell and Bioscience	2017	267
Triptolide: Progress on research in pharmacodynamics and toxicology	Jiang, ZZ	Journal of Ethnopharmacology	2014	255
Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) FH Chen: A review	Wang, ZJ	Journal of Ethnopharmacology	2016	254
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China	Мао, ҮМ	Gastroenterology	2019	244
Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review	Ni, J	Journal of Ethnopharmacology	2015	239

TABLE 3 Top 10 publications with the most citations.

^aWhen a publication contains multiple corresponding authors, only the last one is presented. ^bCited frequency was counted on 13 July 2023.

References	Year St	rength Begin End 2013 - 202
Wang XJ, 2012, J PROTEOME RES, V11, P1284, DOI 10.1021/pr200963e	2012	8.08 2013 2017
Bunchorntavakul C, 2013, ALIMENT PHARM THER, V37, P3, DOI 10.1111/apt.12109	2013	6.93 2013 2016
Lu GH, 2010, PLANTA MED, V76, P825, DOI 10.1055/s-0029-1240688	2010	6.04 2013 2015
Singhuber J, 2009, J ETHNOPHARMACOL, V126, P18, DOI 10.1016/j.jep.2009.07.031	2009	5.68 2013 2014
Liu QY, 2011, INT IMMUNOPHARMACOL, V11, P377, DOI 10.1016/j.intimp.2011.01.012	2011	5.1 2013 2015
Chen CH, 2012, P NATL ACAD SCI USA, V109, P8241, DOI 10.1073/pnas.1119920109	2012	4.95 2013 2017
Jung KA, 2011, GUT LIVER, V5, P493, DOI 10.5009/gnl.2011.5.4.493	2011	9.4 2014 2016
Zhang L, 2012, J ETHNOPHARMACOL, V140, P519, DOI 10.1016/j.jep.2012.01.058	2012	5.57 2014 2017
Tang BW, 2012, J ETHNOPHARMACOL, V141, P134, DOI 10.1016/j.jep.2012.02.011	2012	4.9 2014 2016
Shaw D, 2010, PLANTA MED, V76, P2012, DOI 10.1055/s-0030-1250533	2010	4.73 2014 2015
Zhang JS, 2011, J AGR FOOD CHEM, V59, P9910, DOI 10.1021/jf202266n	2011	4.73 2014 2015
Wang SP, 2012, J ETHNOPHARMACOL, V143, P412, DOI 10.1016/j.jep.2012.07.033	2012	5.69 2015 2017
Teschke R, 2014, ALIMENT PHARM THER, V40, P32, DOI 10.1111/apt.12798	2014	5.38 2015 2018
Zhou Y, 2013, EUR J GASTROEN HEPAT, V25, P825, DOI 10.1097/MEG.0b013e32835f6889	2013	5.12 2015 2016
Siegel R, 2014, CA-CANCER J CLIN, V64, P9	2014	6.61 2016 2019
Chalasani NP, 2014, AM J GASTROENTEROL, V109, P950, DOI 10.1038/ajg.2014.131	2014	5.09 2016 2019
Teschke R, 2015, FRONT PHARMACOL, V6, P0, DOI 10.3389/fphar.2015.00072	2015	4.74 2016 2018
Li XJY, 2014, J ETHNOPHARMACOL, V155, P67, DOI 10.1016/j.jep.2014.06.006	2014	6.51 2018 2019
Lee WJ, 2015, FOOD CHEM TOXICOL, V84, P47, DOI 10.1016/j.fct.2015.06.004	2015	5.44 2018 2020
Frenzel C, 2016, INT J MOL SCI, V17, P0, DOI 10.3390/ijms17050588	2016	4.79 2018 2020
Jing J, 2018, J CLIN TRANSL HEPATO, V6, P57, DOI 10.14218/JCTH.2017.00033	2018	5.9 2019 2022
Meng YK, 2017, ACTA PHARMACOL SIN, V38, P1340, DOI 10.1038/aps.2017.32	2017	5.14 2019 2020
Li CY, 2017, FRONT MED-PRC, V11, P253, DOI 10.1007/s11684-017-0508-9	2017	4.74 2019 2022
Shen T, 2019, GASTROENTEROLOGY, V156, P2230, DOI 10.1053/j.gastro.2019.02.002	2019	6.99 2020 2022
Liu Y, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00364	2018	4.95 2020 2022

Top 25 citations with the strongest bursts.



3,225 publications were included in the analysis, with 2,413 articles, 785 reviews, 12 meeting abstracts, 11 editorial materials and 4 letters.

3.1 Basic characteristics

From 2013 to 2022, with the exception of a slight decline in 2016 (n = 246), annual publications were increased by the year (Figure 1). The number of publications reached its highest in 2022 (n = 475). As showing in Table 1, the top 5 productive journals in this field were Journal of Ethnopharmacology (n = 425), Frontiers in Pharmacology (n = 226), Evidence-Based Complementary and Alternative Medicine (n = 138), Molecules and Phytomedicine (n = 76). Beijing University of Chinese Medicine (n = 187) contributed the most publications. National Natural Science Foundation of China (n = 1,489) is the agency that supported the most publications in this field. The top 5 institutions and funding agencies were all Chinese. Table 2 displays the leading 5 authors alongside their respective h-index values, representing the individuals with the highest number of publications. Xiao-He, Xiao had the most publications and the highest h-index among the authors listed. Figure 2 delineates the publication volume and cooperative connections among countries. China stands out as the most prolific region (n = 2,793), exhibiting collaboration primarily with the United States and Germany.

3.2 Most cited publications and journals

Table 3 lists the 10 most cited publications, with 9 reviews and 1 research article. The publication entitled "The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety (Ekor, 2014)" got the most citations (1,416 citations). Within these 10 publications, 8 were contributed by Chinese researches, 5 were published on the aforenamed top 5 journals. None was published on multidisciplinary journals. Figure 3 shows the temporal burst of cited publications over the last decade in the included publications. "Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum (Li et al., 2017)", "Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (Shen et al., 2019)" and "Polygonum multiflorum Thunb.: A Review on Chemical Analysis, Processing Mechanism, Quality Evaluation, and Hepatotoxicity (Liu et al., 2018)" were emerged as focal points, garnering significant citations in recent years. The top 5 frequently cited journals by the included publications were Journal of Ethnopharmacology (n = 13,159), Frontiers in Pharmacology (n = 5,099), Molecules (n = 1,503), Evidence-Based Complementary and Alternative Medicine (n = 1,489), International Journal of Molecular Sciences (n = 1,347). Figure 4 shows the coupling result of the influential journals. The patterns of journal citations transferred over time, with a recent

TABLE 4 Top 25	keywords	with the	most	frequencies.
----------------	----------	----------	------	--------------

Keyword	Count
Traditional Chinese medicine	263
Apoptosis	190
Pharmacology	168
Toxicity	167
Phytochemistry	143
Hepatotoxicity	119
Oxidative stress	115
Pharmacokinetics	93
Toxicology	93
Metabolomics	88
Inflammation	81
Alzheimer's disease	79
Chinese herbal medicine	75
Network pharmacology	71
Autophagy	66
Traditional uses	56
Triptolide	53
Drug-induced liver injury	48
Herbal medicine	47
Safety	47
Chemotherapy	45
Neuroprotection	43
Meta-analysis	42
Nephrotoxicity	40
Review	39

surge in the popularity of citing journals such as *Frontiers in Pharmacology* and *Phytomedicine*.

3.3 Hotspots and trends

Table 4 lists the top 25 keywords with the most frequencies. In terms of toxic classifications, hepatotoxicity (n = 119) or druginduced liver injury (n = 48), and nephrotoxicity (n = 40) were focused on. In physiological and pathological manifestations, apoptosis (n = 190), oxidative stress (n = 115), inflammation (n = 81) and autophagy (n = 66) were focused on. In methods, pharmacokinetics (n = 93), metabolomics (n = 88), network pharmacology (n = 71), meta-analysis (n = 42) received great attentions.

After co-occurrence clustering of the top 40 keywords, 3 clusters were determined (Figure 5A). The keywords contained in cluster 1 (green cluster) were mainly CHM and its derivative words, which is characterized by the weak connection in-cluster and between-

clusters. Cluster 2 (red cluster) contained the most keywords (n = 19). Among the most frequent words, apoptosis often cooccurred with oxidative stress and autophagy. Keywords in cluster 3 (blue cluster) were closely connected. Toxicity and toxicology often co-occurred with pharmacology or phytochemistry. The two keywords with the strongest correlation were pharmacology and phytochemistry. Figure 5B shows the change of keyword cooccurrence over time. Co-occurring keywords tended to shift from Cluster 1 and Cluster 2 to Cluster 3 between 2020 and 2022.

Figure 6 presents the results of trend topic analysis. Emerging keywords for the past 3 years (2019–2022) included ferroptosis, NLRP3 inflammasome, machine learning, network pharmacology, traditional uses and pharmacology. Long-term concerned keywords (>5 years) included toxicity, safety, angiogenesis and neuroprotection. Short-term concerned keywords (<2 years) included ferroptosis, repellency, LC-MS/MS, aristolochia and contamination.

3.4 Features of publications in the CNKI database

The search in CNKI database generated 5,880 records, comprising 3,306 journal articles, 1894 dissertations, 465 conference articles and 215 other types of publications. Supplementary Figure S1 and Supplementary Table S1 show the frequencies of the top 40 keywords and their co-occurrence network. A substantial portion of the top 40 words exhibited overlap, often conveying similar concepts. In contrast to the WOS database, publications within the CNKI database paid extra attention to the issues in CHM production process, while displaying less attention to the mechanism of CHM toxicity.

4 Discussion

Despite concerns about the toxicity of CHM, its social hazards persist. There is a misconception that CHM is non-toxic and universally applicable. Hence, adverse events caused by the toxicity of CHM occurs in both clinical practice and the public health field. Notably, China experiences a higher proportion of toxic incidents caused by herbs compared to other countries (Yang et al., 2022). As one of the oldest herbal remedies, CHM is often overused outside of prescription. In Asia, it is frequently used as a complementary treatment or health supplement, while in western countries, weight losing is an important purpose (Chen and Fontana, 2021). Therefore, in order to draw attention and provide research directions, it is important to evaluate current research trends.

The number of publications on CHM's toxicity increased in the past decade. The top 5 journals with the most publications have a great influence, with half of the highly cited publications (5/10) included. The *Journal of Ethnopharmacology* was considered the most influential journal within the field, exhibiting the highest publication and citation frequencies. Although most studies were funded and completed by Chinese institutions and authors, publications were concentrated in non-native journals. This highlights the need for more high-quality local journals to



accommodate the growing studies. Similar to other study on toxicity (He et al., 2022), this study found that 9 of the top 10 cited studies were reviews, with only 1 being original research. While reviews contribute to summarizing research progress, this phenomenon may indicate a lack of attention to original research.

In keywords, this study identified hepatotoxicity and nephrotoxicity as the most concerned toxicity categories associated with CHM. Hepatotoxicity is the most common toxicity observed, with over 40 CHMs being identified as potential causes of liver injury (Teschke et al., 2014; Frenzel and Teschke, 2016). Among these toxic substances, alkaloids and terpenoids represent the two primary groups associated with hepatotoxic effects (He et al., 2019). Nephrotoxic components in CHM, particularly aristolochic acid, were among the earliest lethal toxic components identified in CHM. Besides, additional components that cause nephrotoxicity include alkaloids and anthraquinones. Although certain toxicities related to CHM were reported, including neurotoxicity (e.g., *Tripterygium wilfordi* (Liu et al., 2019)), cardiotoxicity (e.g., Aconitum carmichaeli (Sun et al., 2018)), and reproductive toxicity (e.g., Rhizoma Pinelliae (Li et al., 2022)), these do not exhibit high keyword frequency. This could be attributed to the fact that many CHMs possess a multitoxic nature, including hepatotoxicity or nephrotoxicity. Apoptosis was the most concerned pathological mechanism, which is quite complex. Toxic components such as triptolide and aristolochic acid can induce apoptosis to cause damage (Romanov et al., 2015; Wang Y. et al., 2018). Conversely, oxymatrine in Sophora flavescens may promote apoptosis to provide anti-cancer effect (Lan et al., 2020). In addition, evidence suggest that emodin in several CHMs can reduce the toxicity of cisplatin by inhibiting apoptosis (Liu et al., 2016). In methodology, the diversity reflected in the keywords of highfrequency, including various experimental and statistical methods. Regarding toxic ingredients, triptolide (n = 53), flavonodis (n = 25) and aristolochic acid (n = 21) keywords used over 20 times each. Expect aristolochic acids, as the most classic toxic ingredient, the other two exhibit dual characteristics.



Triptolide functions as both an active and toxic ingredient, showcasing antitumor properties alongside notable hepatotoxic, nephrotoxic, and cardiotoxic tendencies (Noel et al., 2019). Flavonoids exists in most plant species, yet certain members within this category carry nephrotoxic properties (Yang et al., 2018). Other classic toxic components received less attention in keyword mentions, likely attributable to the prohibition of corresponding CHM, consequently diminishing research focus.

Co-occurrence clustering analysis identified 3 clusters related to CHM, mechanism and pharmacology, respectively. Although all included publications involved both CHM and toxicity, the connection between these 2 words and their derivatives were relatively loose. This may be attributed to studies focusing predominantly on one keyword and giving less attention to the other, leading to a low frequency of co-occurrence. Therefore, there remains insufficient studies that directly explore the intersection of CHM and toxicity. Keywords with short-term durations indicate limited research importance in these topics. In long-term keywords, apart from toxicity and safety, angiogenesis and neuroprotection had weak correlation with CHM's toxicity itself. On the contrary, some low-toxicity CHMs were shown to possess neuroprotective or anti-angiogenic properties, thereby reducing neurotoxicity or cardiotoxicity induced by other drugs (Cheng et al., 2016; Li et al., 2019). These keywords could provide new insights into the relationship between CHM and toxicity. Emerging keywords in the past 3 years included 2 mechanism-related terms and 2 methodological terms. Within the mechanism category, ferroptosis is a non-apoptotic form of cell death, which is also an effective index for monitoring kidney injury (Jiang et al., 2021; Zeng et al., 2023). A recent study indicated that certain CHMs containing arsenic can induce kidney injury through the induction of ferroptosis (Zhang et al., 2022). The NLRP3 inflammasome was recognized as a trigger for liver injury (Mridha et al., 2017). In CHMs, Epimedium brevicornu and *Psoralea corylifolia* were proved to cause liver injury by enhancing NLRP3 inflammasome activation (Wang et al., 2020; Qin et al., 2021). Therefore, further studies concerning hepatotoxicity and nephrotoxicity in CHMs could take these 2 topics into consideration. Machine learning and network pharmacology were emerging technologies in the field of pharmacology. In the study of CHM, machine learning exists the potential in predicting toxicity (Zulkifli et al., 2023), while network pharmacology could be utilized to compensate for the limitations of traditional research methods in understanding the multi-component synergism of CHM (Yuan et al., 2017). Although landmark achievements in these 2 methods within CHM toxicity research are currently limited, they hold potential for future directions. It should be emphasized that these methods, based on existing evidence, rely on the accumulation of data from original studies.

One limitation is that the study was conducted on existing publications, which was unable to represent undiscovered research directions. Despite this common shortcoming of this type of research, this study attempted to explore future research directions by summarizing emerging keywords. Another limitation is that the influence of a journal or individual publication may not be fully consistent with the number of citations received. Aside from publication time and exposure, citation rate may even be affected by the popularity of the publisher or author (Hirsch, 2005). To mitigate this limitation, this study included only publications from the last 10 years to avoid diluting recent trends with outdated studies or methods. Additionally, potential bias may arise from the constraint of current software in merging database analyses. In order to mitigate this source of error, WOS was designated as the principal database for analysis, with supplementary examination of the CNKI database aimed at exploring divergences between the two databases.

5 Conclusion

Concerns about the toxicity of CHM have increased in the past decade. However, there remains insufficient studies that directly explore the intersection of CHM and toxicity. Hepatotoxicity and nephrotoxicity, as the most concerned toxicity classifications associated with CHM, warrant more in-depth investigations. Apoptosis was the most concerned toxicological mechanism. As a recent increase in attention, exploring the mechanisms of ferroptosis in nephrotoxicity and NLRP3 inflammasome in hepatotoxicity could provide valuable insights. Machine learning and network pharmacology are potential methods for future studies.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

K-XZ: Data curation, Investigation, Methodology, Writing-original draft. MW: Investigation, Writing-original draft. Z-LB: Formal Analysis, Resources, Software, Visualization, Writing-review and editing. S-LH: Writing-review and editing. L-MF: Writing-review and editing. F-FG: Formal Analysis, Resources, Software, Visualization, Writing-review and editing. X-ZW: Conceptualization, Formal Analysis, Resources, Software, Supervision, Visualization, Writing-review and editing. S-FX: Project administration, Supervision, Validation, Writing-review and editing.

References

Barnes, J., McLachlan, A. J., Sherwin, C. M., and Enioutina, E. Y. (2016). Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. *Expert Rev. Clin. Pharmacol.* 9, 905–915. doi:10.1586/17512433.2016.1171712

Chen, V. L., and Fontana, R. J. (2021). Are herbals more hepatotoxic than prescription medications. *Hepatol. Int.* 15, 1301–1304. doi:10.1007/s12072-021-10256-w

Cheng, J. H., Tsai, C. L., Lien, Y. Y., Lee, M. S., and Sheu, S. C. (2016). High molecular weight of polysaccharides from Hericium erinaceus against amyloid beta-induced neurotoxicity. *BMC Complement. Altern. Med.* 16, 170. doi:10.1186/s12906-016-1154-5

Donaldson, L. J., Kelley, E. T., Dhingra-Kumar, N., Kieny, M. P., and Sheikh, A. (2017). Medication without harm: WHO's third global patient safety challenge. *Lancet* 389, 1680–1681. doi:10.1016/S0140-6736(17)31047-4

Ekor, M. (2014). The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front. Pharmacol.* 4, 177. doi:10.3389/ fphar.2013.00177

Frenzel, C., and Teschke, R. (2016). Herbal hepatotoxicity: clinical characteristics and listing compilation. *Int. J. Mol. Sci.* 17, 588. doi:10.3390/ijms17050588

Gabardi, S., Munz, K., and Ulbricht, C. (2007). A review of dietary supplementinduced renal dysfunction. *Clin. J. Am. Soc. Nephrol.* 2, 757–765. doi:10.2215/CJN. 00500107

Hao, P., Jiang, F., Cheng, J., Ma, L., Zhang, Y., and Zhao, Y. (2017). Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. *J. Am. Coll. Cardiol.* 69, 2952–2966. doi:10.1016/j.jacc.2017.04.041

Hashimoto, K., Higuchi, M., Makino, B., Sakakibara, I., Kubo, M., Komatsu, Y., et al. (1999). Quantitative analysis of aristolochic acids, toxic compounds, contained in some medicinal plants. *J. Ethnopharmacol.* 64, 185–189. doi:10. 1016/s0378-8741(98)00123-8

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the fifth batch of training objects of the national TCM clinical outstanding talents training program (National Letter of TCM Education [2022] No. 1), the Key Project of Jiangsu Provincial Health Commission (ZD2021042) and the Natural Science Foundation for Nanjing University of Chinese Medicine (XZR2020029).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1293468/ full#supplementary-material

He, S., Zhang, C., Zhou, P., Zhang, X., Ye, T., Wang, R., et al. (2019). Herb-induced liver injury: phylogenetic relationship, structure-toxicity relationship, and herb-ingredient network analysis. *Int. J. Mol. Sci.* 20, 3633. doi:10.3390/ijms20153633

He, T., Ao, J., Duan, C., Yan, R., Li, X., Liu, L., et al. (2022). Bibliometric and visual analysis of nephrotoxicity research worldwide. *Front. Pharmacol.* 13, 940791. doi:10. 3389/fphar.2022.940791

Hirsch, J. E. (2005). An index to quantify an individual's scientific research output. Proc. Natl. Acad. Sci. U.S.A. 102, 16569–16572. doi:10.1073/pnas.0507655102

Hoppmann, N. A., Gray, M. E., and McGuire, B. M. (2020). Drug-induced liver injury in the setting of chronic liver disease. *Clin. Liver Dis.* 24, 89–106. doi:10.1016/j.cld.2019. 09.006

Jakobsson, P. J., Robertson, L., Welzel, J., Zhang, M., Zhihua, Y., Kaixin, G., et al. (2022). Where traditional Chinese medicine meets Western medicine in the prevention of rheumatoid arthritis. *J. Intern. Med.* 292, 745–763. doi:10.1111/joim.13537

Jiang, X., Stockwell, B. R., and Conrad, M. (2021). Ferroptosis: mechanisms, biology and role in disease. *Nat. Rev. Mol. Cell Biol.* 22, 266–282. doi:10.1038/s41580-020-00324-8

Kulkarni, P. (2021). Prediction of drug-induced kidney injury in drug discovery. *Drug Metab. Rev.* 53, 234–244. doi:10.1080/03602532.2021.1922436

Lan, X., Zhao, J., Zhang, Y., Chen, Y., Liu, Y., and Xu, F. (2020). Oxymatrine exerts organ- and tissue-protective effects by regulating inflammation, oxidative stress, apoptosis, and fibrosis: from bench to bedside. *Pharmacol. Res.* 151, 104541. doi:10. 1016/j.phrs.2019.104541

Lee, T. Y., Wu, M. L., Deng, J. F., and Hwang, D. F. (2002). High-performance liquid chromatographic determination for aristolochic acid in medicinal plants and slimming products. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 766, 169–174. doi:10.1016/s0378-4347(01)00416-9

Li, C., Niu, M., Bai, Z., Zhang, C., Zhao, Y., Li, R., et al. (2017). Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum. *Front. Med.* 11, 253–265. doi:10.1007/s11684-017-0508-9

Li, J., Wu, Y., Wang, D., Zou, L., Fu, C., Zhang, J., et al. (2019). Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. *Pharmacol. Res.* 146, 104313. doi:10.1016/j.phrs.2019.104313

Li, Q., Yan, X., Zhang, Y., Zhou, J., Yang, L., Wu, S., et al. (2022). Risk compounds, potential mechanisms and biomarkers of traditional Chinese medicine-induced reproductive toxicity. *J. Appl. Toxicol.* 42, 1734–1756. doi:10.1002/jat.4290

Liu, C., Zhang, C., Wang, W., Yuan, F., He, T., Chen, Y., et al. (2019). Integrated metabolomics and network toxicology to reveal molecular mechanism of celastrol induced cardiotoxicity. *Toxicol. Appl. Pharmacol.* 383, 114785. doi:10.1016/j.taap.2019. 114785

Liu, H., Gu, L. B., Tu, Y., Hu, H., Huang, Y. R., and Sun, W. (2016). Emodin ameliorates cisplatin-induced apoptosis of rat renal tubular cells *in vitro* by activating autophagy. *Acta Pharmacol. Sin.* 37, 235–245. doi:10.1038/aps.2015.114

Liu, S. H., Chuang, W. C., Lam, W., Jiang, Z., and Cheng, Y. C. (2015). Safety surveillance of traditional Chinese medicine: current and future. *Drug Saf.* 38, 117–128. doi:10.1007/s40264-014-0250-z

Liu, Y., Wang, Q., Yang, J., Guo, X., Liu, W., Ma, S., et al. (2018). Polygonum multiflorum Thunb.: a review on chemical analysis, processing mechanism, quality evaluation, and hepatotoxicity. *Front. Pharmacol.* 9, 364. doi:10.3389/fphar.2018.00364

Lv, W., Piao, J. H., and Jiang, J. G. (2012). Typical toxic components in traditional Chinese medicine. Expert Opin. Drug Saf. 11, 985–1002. doi:10.1517/14740338.2012.726610

Ma, Z. T., Shi, Z., Xiao, X. H., and Wang, J. B. (2023). New insights into herb-induced liver injury. *Antioxid. Redox Signal.* 38, 1138–1149. doi:10.1089/ars.2022.0134

Mridha, A. R., Wree, A., Robertson, A., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., et al. (2017). NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037–1046. doi:10.1016/j.jhep.2017.01.022

Noel, P., Von Hoff, D. D., Saluja, A. K., Velagapudi, M., Borazanci, E., and Han, H. (2019). Triptolide and its derivatives as cancer therapies. *Trends Pharmacol. Sci.* 40, 327–341. doi:10.1016/j.tips.2019.03.002

Qin, N., Xu, G., Wang, Y., Zhan, X., Gao, Y., Wang, Z., et al. (2021). Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity. *Front. Med.* 15, 594–607. doi:10.1007/s11684-020-0809-2

Qu, L., Li, X., Xiong, Y., Wang, Z., Zhou, Y., Zou, W., et al. (2022). Opportunities and hurdles to European market access for multi-herbal traditional Chinese medicine products: an analysis of EU regulations for combination herbal medicinal products. *Pharmacol. Res.* 186, 106528. doi:10.1016/j.phrs.2022.106528

Raynor, D. K., Dickinson, R., Knapp, P., Long, A. F., and Nicolson, D. J. (2011). Buyer beware? Does the information provided with herbal products available over the counter enable safe use. *BMC Med.* 9, 94. doi:10.1186/1741-7015-9-94

Romanov, V., Whyard, T. C., Waltzer, W. C., Grollman, A. P., and Rosenquist, T. (2015). Aristolochic acid-induced apoptosis and G2 cell cycle arrest depends on ROS generation and MAP kinases activation. *Arch. Toxicol.* 89, 47–56. doi:10.1007/s00204-014-1249-z

Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., et al. (2019). Incidence and Etiology of drug-induced liver injury in mainland China. *Gastroenterology* 156, 2230–2241. doi:10.1053/j.gastro.2019.02.002

Sun, W., Yan, B., Wang, R., Liu, F., Hu, Z., Zhou, L., et al. (2018). *In vivo* acute toxicity of detoxified Fuzi (lateral root of Aconitum carmichaeli) after a traditional detoxification process. *EXCLI J.* 17, 889–899. doi:10.17179/excli2018-1607

Teng, L., Zu, Q., Li, G., Yu, T., Job, K. M., Yang, X., et al. (2016). Herbal medicines: challenges in the modern world. Part 3. China and Japan. *Expert Rev. Clin. Pharmacol.* 9, 1225–1233. doi:10.1080/17512433.2016.1195263

Teschke, R., Wolff, A., Frenzel, C., and Schulze, J. (2014). Review article: herbal hepatotoxicity--an update on traditional Chinese medicine preparations. *Aliment. Pharmacol. Ther.* 40, 32–50. doi:10.1111/apt.12798

Tu, Y. (2016). Artemisinin-A gift from traditional Chinese medicine to the world (Nobel lecture). *Angewandte Chemie Int. ed. Engl.* 55, 10210–10226. doi:10.1002/anie. 201601967

van Eck, N. J., and Waltman, L. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics* 84, 523–538. doi:10.1007/s11192-009-0146-3

Vanhaelen, M., Vanhaelen-Fastre, R., But, P., and Vanherweghem, J. L. (1994). Identification of aristolochic acid in Chinese herbs. *Lancet* 343, 174. doi:10.1016/s0140-6736(94)90964-4

Wang, J., Song, H., Ge, F., Xiong, P., Jing, J., He, T., et al. (2022). Landscape of DILIrelated adverse drug reaction in China Mainland. *Acta Pharm. Sin. B* 12, 4424–4431. doi:10.1016/j.apsb.2022.04.019

Wang, L., Ding, X., Li, C., Zhao, Y., Yu, C., Yi, Y., et al. (2018a). Oral administration of Aristolochia manshuriensis Kom in rats induces tumors in multiple organs. *J. Ethnopharmacol.* 225, 81–89. doi:10.1016/j.jep.2018.07.001

Wang, Y., Guo, S. H., Shang, X. J., Yu, L. S., Zhu, J. W., Zhao, A., et al. (2018b). Triptolide induces Sertoli cell apoptosis in mice via ROS/INK-dependent activation of the mitochondrial pathway and inhibition of Nrf2-mediated antioxidant response. Acta Pharmacol. Sin. 39, 311–327. doi:10.1038/aps.2017.95

Wang, Z., Xu, G., Wang, H., Zhan, X., Gao, Y., Chen, N., et al. (2020). Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation. Acta Pharm. Sin. B 10, 1619–1633. doi:10.1016/j. apsb.2020.03.006

Yang, B., Xie, Y., Guo, M., Rosner, M. H., Yang, H., and Ronco, C. (2018). Nephrotoxicity and Chinese herbal medicine. *Clin. J. Am. Soc. Nephrol.* 13, 1605–1611. doi:10.2215/CJN.11571017

Yang, Y., Ge, F. L., Tang, J. F., Qin, S. L., Zeng, R., Yao, M. L., et al. (2022). A review of herb-induced liver injury in mainland China. *Front. Pharmacol.* 13, 813073. doi:10. 3389/fphar.2022.813073

Yao, C. L., Zhang, J. Q., Li, J. Y., Wei, W. L., Wu, S. F., and Guo, D. A. (2021). Traditional Chinese medicine (TCM) as a source of new anticancer drugs. *Nat. Prod. Rep.* 38, 1618–1633. doi:10.1039/d0np00057d

You, L., Liang, K., An, R., and Wang, X. (2022). The path towards FDA approval: a challenging journey for Traditional Chinese Medicine. *Pharmacol. Res.* 182, 106314. doi:10.1016/j.phrs.2022.106314

Yuan, H., Ma, Q., Cui, H., Liu, G., Zhao, X., Li, W., et al. (2017). How can synergism of traditional medicines benefit from network pharmacology. *Molecules* 22, 1135. doi:10. 3390/molecules22071135

Zeng, F., Nijiati, S., Liu, Y., Yang, Q., Liu, X., Zhang, Q., et al. (2023). Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries. *Sci. Adv.* 9, eadd8539. doi:10.1126/sciadv.add8539

Zhang, S., Cao, S., Zhou, H., Li, L., Hu, Q., Mao, X., et al. (2022). Realgar-induced nephrotoxicity via ferroptosis in mice. *J. Appl. Toxicol.* 42, 1843–1853. doi:10.1002/jat. 4362

Zhong, Y., Menon, M. C., Deng, Y., Chen, Y., and He, J. C. (2015). Recent advances in traditional Chinese medicine for kidney disease. *Am. J. Kidney Dis.* 66, 513–522. doi:10. 1053/j.ajkd.2015.04.013

Zhou, J., Ouedraogo, M., Qu, F., and Duez, P. (2013). Potential genotoxicity of traditional Chinese medicinal plants and phytochemicals: an overview. *Phytother. Res.* 27, 1745–1755. doi:10.1002/ptr.4942

Zulkifli, M. H., Abdullah, Z. L., Mohamed Yusof, N., and Mohd Fauzi, F. (2023). *In silico* toxicity studies of traditional Chinese herbal medicine: a mini review. *Curr. Opin. Struct. Biol.* 80, 102588. doi:10.1016/j.sbi.2023.102588